Weissella cibaria CMU,
does it really help with Improvement of gingivitis and gum bleeding?
research showsThe proprietary OraCMU strain has signals of improvement in the gingival index (GI) and bleeding on probing (BOP) in eight-week double-blind trials. In an 80-participant 2026 trial, GI and BOP decreased more than with placebo, but a 2020 trial analyzed only 68 of 92 randomized participants and did not find clear overall effects across GI and BOP. All outcomes are short-term, with no evidence on long-term periodontitis progression or tooth loss, supporting C.
ads claimMarketing expands these findings into claims of blocking the cause of gum disease, protecting alveolar bone, or preventing periodontitis. The public human evidence directly addresses eight-week GI and BOP changes and microbial or inflammatory markers, not prevention of periodontitis progression or tooth loss.
Useful facts when choosing a product
- OraCMU is registered in Korea as individually recognized ingredient 2026-2 for gum health and is not equivalent to ordinary oral-probiotic candy products.
- The 2026 trial used tablets labeled 2.0 x 10^8 CFU/g twice daily for eight weeks. The 2020 trial used an 800 mg tablet containing 1.0 x 10^8 CFU/g once daily.
- The CMU strain designation, viable count through the time of use, and tablet directions matter. Results cannot be transferred to JW15, CMS1, or mixed oral probiotics.
- No serious adverse events were reported over eight weeks, but long-term safety evidence is limited. People with immunocompromise, severe illness, or central venous catheters should seek professional advice before using live probiotics.
What the research actually shows
Kang 2020 randomized 92 young adults without periodontitis after scaling to OraCMU or placebo but analyzed only 68. BOP improved at selected maxillary sites, while overall BOP change and between-group differences in probing depth, GI, and plaque index were not significant. Jeon 2026 gave tablets containing OraCMU at 2.0 x 10^8 CFU/g or placebo twice daily for eight weeks to 80 adults with gingivitis or incipient periodontitis and found improvements in GI, BOP, selected inflammatory proteins, and periodontal pathogens. A separate 2026 paper sharing the same registration used halitosis as the primary outcome and GI and BOP as secondary outcomes. No long-term follow-up is available.
Why this is classified as C (54)
The latest 80-participant double-blind trial was positive for GI and BOP, but the earlier trial did not show consistent overall clinical-index effects. Evidence is tied to a specific proprietary strain, eight-week surrogate outcomes, and an individually recognized ingredient, with no long-term periodontal outcomes. This supports C with 55 points.
Counterpoint. A short-term adjunctive improvement in GI and BOP remains possible in adults with gingivitis. This does not establish replacement of brushing, interdental care, or scaling, or prevention of long-term periodontitis.
Rejudgment record. New verdict — Accepted positive eight-week GI and BOP findings for the CMU strain but capped the grade at C for partial earlier results, proprietary-strain short-term surrogates, and absence of long-term periodontal outcomes
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement of gingival index and bleeding on probing over eight weeks | C | The latest 80-participant trial was positive, but overall indices in the earlier trial were only partially positive. |
| Prevention of long-term periodontitis progression or tooth loss | ? | Direct long-term human outcomes are absent. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Kang MS et al. 2020 | Eight-week randomized double-blind placebo-controlled trial | 68 | Korean government and NRF funding; OraPharm investigator participation and product supply | BOP, probing depth, GI, plaque index, and oral microbiota | BOP improved at selected maxillary sites, but overall BOP change and probing depth, GI, and plaque index did not differ significantly between groups. | Key |
| Jeon HW et al. 2026 | Eight-week randomized double-blind placebo-controlled trial | 80 | Chosun University research fund; Oraticx investigator participation | Primary GI; secondary BOP, probing depth, attachment level, inflammatory proteins, and microbiota | Reductions in GI and BOP were greater than with placebo, with decreases in selected inflammatory proteins and periodontal pathogens. | Key |
| MFDS recognition 2026-2 | Registration as an individually recognized functional ingredient | Applicant: Oraticx | Gum-health functional labeling | OraCMU was registered as ingredient 2026-2, but regulatory recognition itself is not an independent efficacy grade. | Regulatory context |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] Weissella cibaria CMU x improvement of gingivitis and gum bleeding — Evidence Grade C·54. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/general/weissella-cibaria-cmu-gingivitis-gum-bleeding/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.